Agios Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of medicines in the field of cellular metabolism and adjacent areas of biology. The company offers TIBSOVO (ivosidenib), an oral targeted inhibitor for treating adult patients with relapsed or refractory acute myeloid leukemia (R/R AML), as well as to treat patients with newly diagnosed AML; and IDHIFA (enasidenib), an oral targeted inhibitor for patients with R/R AML and an isocitrate dehydrogenase 2 mutation. It is also developing TIBSOVO, which has completed Phase II clinical trials to treat IC eligible frontline AML; that is in Phase III clinical trials for treating IC ineligible frontline AML; and that is in Phase III clinical trials for the treatment of cholangiocarcinoma, as well as in early stage clinical development to treat glioma and solid tumors. In addition, the company is developing IDHIFA, which has completed Phase II clinical study for treating IC eligible frontline AML; and that is in Phase I/II clinical trials for the treatment of IC ineligible frontline AML. Further, it is developing mitapivat, which is in Phase III clinical trials to treat pyruvate kinase deficiency, as well as in Phase II clinical study for treating thalassemia and sickle cell disease; vorasidenib (AG-881) that is in Phase I clinical trials for the treatment of solid tumors, including glioma; AG-270, which is in Phase I dose-escalation trial to treat methylthioadenosine phosphorylase deleted tumors; and AG-946 that is in Phase I clinical study for treating hemolytic anemias and other indications. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is based in Cambridge, Massachusetts. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Washburn Theodore James Jr. | Principal Accounting Officer | Feb 25 | Sale | 30.00 | 108 | 3,240 | 2,549 | Mar 01 04:54 PM | Washburn Theodore James Jr. | Principal Accounting Officer | Feb 22 | Option Exercise | 0.00 | 167 | 0 | 2,716 | Feb 23 04:09 PM | Schenkein David P | Director | Feb 22 | Option Exercise | 0.00 | 2,775 | 0 | 117,052 | Feb 23 04:09 PM | Burns James William | Chief Legal Officer | Feb 22 | Option Exercise | 0.00 | 724 | 0 | 15,008 | Feb 23 04:10 PM | Poddar Richa | Chief Commercial Officer | Feb 22 | Option Exercise | 0.00 | 658 | 0 | 5,183 | Feb 23 04:11 PM | Gheuens Sarah | Chief Medical Officer | Feb 18 | Option Exercise | 0.00 | 3,271 | 0 | 8,723 | Feb 23 04:12 PM | Poddar Richa | Chief Commercial Officer | Feb 18 | Option Exercise | 0.00 | 1,884 | 0 | 4,525 | Feb 23 04:11 PM | FOUSE JACQUALYN A | Chief Executive Officer | Feb 18 | Option Exercise | 0.00 | 12,379 | 0 | 78,571 | Feb 23 04:10 PM | Biller Jonathan | Chief Financial Officer | Feb 18 | Option Exercise | 0.00 | 8,523 | 0 | 25,641 | Feb 23 04:10 PM | Car Bruce | Chief Scientific Officer | Feb 18 | Option Exercise | 0.00 | 6,874 | 0 | 18,793 | Feb 23 04:11 PM | Washburn Theodore James Jr. | Principal Accounting Officer | Feb 16 | Sale | 30.81 | 233 | 7,179 | 2,549 | Feb 18 04:56 PM | Washburn Theodore James Jr. | Principal Accounting Officer | Feb 14 | Option Exercise | 0.00 | 360 | 0 | 3,413 | Feb 16 05:00 PM | Poddar Richa | Chief Commercial Officer | Feb 14 | Option Exercise | 0.00 | 1,738 | 0 | 3,231 | Feb 16 05:00 PM | Burns James William | Chief Legal Officer | Feb 14 | Option Exercise | 0.00 | 6,988 | 0 | 16,439 | Feb 16 05:01 PM | FOUSE JACQUALYN A | Chief Executive Officer | Feb 14 | Option Exercise | 0.00 | 11,334 | 0 | 69,697 | Feb 16 05:01 PM | Washburn Theodore James Jr. | Principal Accounting Officer | Feb 14 | Sale | 31.25 | 504 | 15,750 | 2,782 | Feb 16 05:00 PM | Biller Jonathan | Chief Financial Officer | Feb 10 | Option Exercise | 0.00 | 3,667 | 0 | 18,467 | Feb 14 04:08 PM | Burns James William | Chief Legal Officer | Feb 10 | Option Exercise | 0.00 | 1,833 | 0 | 10,094 | Feb 14 04:06 PM | Poddar Richa | Chief Commercial Officer | Feb 10 | Option Exercise | 0.00 | 2,068 | 0 | 2,218 | Feb 14 04:06 PM | Washburn Theodore James Jr. | Principal Accounting Officer | Feb 10 | Option Exercise | 0.00 | 777 | 0 | 3,292 | Feb 14 04:08 PM | Gheuens Sarah | Chief Medical Officer | Feb 10 | Option Exercise | 0.00 | 2,162 | 0 | 6,210 | Feb 14 04:09 PM | Car Bruce | Chief Scientific Officer | Feb 10 | Option Exercise | 0.00 | 3,667 | 0 | 12,992 | Feb 14 04:07 PM | Car Bruce | Chief Scientific Officer | Jan 06 | Option Exercise | 0.00 | 3,437 | 0 | 10,530 | Jan 10 04:06 PM | Biller Jonathan | Chief Financial Officer | Dec 03 | Option Exercise | 0.00 | 5,753 | 0 | 16,623 | Dec 07 04:18 PM | Gheuens Sarah | Chief Medical Officer | Dec 02 | Option Exercise | 0.00 | 834 | 0 | 4,296 | Dec 07 04:18 PM | Alenson Carman | Principal Accounting Officer | Jun 21 | Option Exercise | 51.51 | 1,777 | 91,533 | 1,777 | Jun 23 05:28 PM | Alenson Carman | Principal Accounting Officer | Jun 21 | Sale | 61.61 | 1,777 | 109,481 | 0 | Jun 23 05:28 PM | Bowden Christopher | Chief Medical Officer | Jun 18 | Option Exercise | 49.99 | 48,493 | 2,423,991 | 63,980 | Jun 22 04:44 PM | Bowden Christopher | Chief Medical Officer | Jun 18 | Sale | 60.11 | 48,493 | 2,914,851 | 15,487 | Jun 22 04:44 PM | Bowden Christopher | Chief Medical Officer | Jun 17 | Option Exercise | 39.76 | 2,502 | 99,480 | 17,989 | Jun 21 04:18 PM | Bowden Christopher | Chief Medical Officer | Jun 17 | Sale | 60.02 | 2,502 | 150,170 | 15,487 | Jun 21 04:18 PM | Bowden Christopher | Chief Medical Officer | Jun 10 | Option Exercise | 39.76 | 20,853 | 829,115 | 36,340 | Jun 11 05:00 PM | Bowden Christopher | Chief Medical Officer | Jun 10 | Sale | 60.06 | 20,853 | 1,252,437 | 15,487 | Jun 11 05:00 PM | Bowden Christopher | Chief Medical Officer | Jun 09 | Option Exercise | 39.76 | 7,149 | 284,244 | 22,636 | Jun 11 05:00 PM | Bowden Christopher | Chief Medical Officer | Jun 09 | Sale | 60.16 | 7,149 | 430,117 | 15,487 | Jun 11 05:00 PM | Bowden Christopher | Chief Medical Officer | Jun 08 | Option Exercise | 39.76 | 6,675 | 265,398 | 22,162 | Jun 09 04:06 PM | Bowden Christopher | Chief Medical Officer | Jun 08 | Sale | 60.07 | 6,675 | 400,939 | 15,487 | Jun 09 04:06 PM | Bowden Christopher | Chief Medical Officer | Jun 07 | Option Exercise | 39.76 | 4,268 | 169,696 | 19,755 | Jun 09 04:06 PM | Bowden Christopher | Chief Medical Officer | Jun 07 | Sale | 60.04 | 4,268 | 256,232 | 15,487 | Jun 09 04:06 PM | MARAGANORE JOHN | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 28,443 | Jun 02 04:09 PM | CLARK IAN T | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 4,964 | Jun 02 04:09 PM | Schenkein David P | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 114,277 | Jun 02 04:07 PM | Clancy Paul J | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 4,964 | Jun 02 04:07 PM | Foster-Cheek Kaye I | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 7,164 | Jun 02 04:08 PM | Scadden David | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 5,535 | Jun 02 04:07 PM | Ho Maykin | Director | May 28 | Option Exercise | 0.00 | 1,686 | 0 | 4,964 | Jun 02 04:06 PM |
|